News
AstraZeneca Pill Cut Risk of Breast Cancer Death, Study Finds
Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding that could change the way such cancers are treated,
Often, when young women approach their care teams with concerns about breast cancer, they're brushed aside. It’s our ...
33mon MSN
In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...
Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if ...
Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...
A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid ...
Stephanie Walker was diagnosed with metastatic breast cancer (MBC) nearly a decade ago — an experience she says transformed ...
Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that ...
The gathering in Tampa drew women from as as far as Europe. It was organized by the Breast Implant Safety Alliance, a ...
A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...
Thousands of islanders are set to walk across Guernsey next month, to mark 10 years of a breast cancer charity's sunset walks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback